Kuraray (3405) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
13 Jun, 2025Executive summary
Net sales for FY2024 3Q rose 7.0% year-over-year to ¥614.8 billion; operating income increased 19.8% to ¥73.9 billion; net income attributable to owners was ¥46.6 billion, up 27.8%.
Growth was driven by stable U.S. consumption, gradual European recovery, and demand recovery in key segments, despite uncertainty from geopolitical tensions and Chinese economic stagnation.
All major segments except Isoprene posted higher operating income; Isoprene saw a decline despite sales growth.
Financial highlights
Gross profit increased to ¥207.6 billion; operating margin improved as SG&A expenses rose slower than sales.
Ordinary income climbed 21.8% year-over-year to ¥70.3 billion; EPS for the period was ¥140.83.
Equity ratio improved to 58.1% as of September 30, 2024; total assets stable at ¥1,254.3 billion.
Comprehensive income for the period was ¥51.6 billion, down 49.7% year-over-year due to lower foreign currency translation gains.
Interest-bearing debt decreased by ¥25.8 billion during the period.
Outlook and guidance
FY2024 net sales forecast revised to ¥835.0 billion, operating income to ¥89.0 billion, and net income to ¥55.0 billion.
Guidance unchanged from previous update; expects continued profit growth over FY2023.
Annual dividend forecast raised to ¥54 per share; share buyback and cancellation of 30 million shares (8.45% of total) to enhance shareholder returns.
Latest events from Kuraray
- FY2025 profit dropped on impairments, but FY2026 forecasts a strong rebound and higher dividends.3405
Q4 202610 Feb 2026 - SentryGlas® dominates structural glass with high performance and sustainability, driving global growth.3405
Investor Update19 Dec 2025 - Profits fell over 50% year-over-year; forecasts cut and major share buyback completed.3405
Q3 202612 Nov 2025 - Profits and sales fell in 1H FY2025, but portfolio restructuring and buybacks advanced.3405
Q2 20268 Aug 2025 - High-performance PVOH products and cell culture solutions drive robust global growth outlook.3405
Investor Day 202519 Jun 2025 - Record interim results and upgraded outlook, with increased dividends and share buybacks.3405
Q2 202513 Jun 2025 - Sales up, profits down; full-year outlook steady, major share buyback planned.3405
Q1 20266 Jun 2025 - Record sales and operating income, but net income fell on extraordinary losses; profit recovery forecast.3405
Q4 20255 Jun 2025